Metronidazole Baxter (Metronidazole)

Metronidazole enters anaerobic microorganisms and is reduced by their electron transport proteins. The reduced nitro group generates reactive intermediates that bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, which leads to cell death of the targeted bacteria or protozoa.

The dosing regimen for Metronidazole Baxter is determined by the prescribing clinician based on the type and severity of the infection, patient weight, renal and hepatic function, and local treatment guidelines. No fixed dose is provided here.

Metronidazole is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy when clearly needed, but it is generally avoided in the first trimester. Limited amounts are excreted in breast milk; clinicians should weigh benefits against potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if required), and necessary import documentation.

Metronidazole is often preferred for anaerobic infections because of its excellent tissue penetration and activity against a broad range of obligate anaerobes. Alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations may be used, but metronidazole typically offers a narrower spectrum with fewer drug‑interaction concerns, making it a first‑line choice in many hospital protocols.

Metronidazole Baxter should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it may be used within the time frame specified by the manufacturer, but refrigeration should be restored promptly.

Metronidazole Baxter is given by intravenous infusion. The solution is diluted in an appropriate compatible IV fluid and administered over a period recommended by the prescriber, usually ranging from 30 minutes to several hours, depending on the infection severity and patient tolerance.

Serious adverse reactions include seizures, peripheral neuropathy, severe skin reactions such as Stevens‑Johnson syndrome, and life‑threatening allergic responses (anaphylaxis). Patients should be monitored for neurological symptoms, skin changes, or signs of hypersensitivity, and therapy should be discontinued immediately if any of these events occur.

Metronidazole Baxter is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is also advised for individuals with severe hepatic impairment, those receiving disulfiram, and patients with a history of seizures or neuropathy unless the benefits outweigh the risks.